Skip to main content
BIOVIE INC. logo

BIOVIE INC. — Investor Relations & Filings

Ticker · BIVI ISIN · US09074F4054 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2019-07-09 Regulatory Filings
Country US United States of America
Listing US BIVI

About BIOVIE INC.

https://www.bioviepharma.com/

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for chronic debilitating conditions. The company's pipeline focuses on neurological and neurodegenerative disorders as well as advanced liver disease. Its lead drug candidate, bezisterim, is being studied for Alzheimer's disease based on the hypothesis that modulating inflammation and enhancing insulin sensitivity in the brain can improve cognitive function and provide neuroprotection. Other areas of focus include Parkinson's disease, ascites (a common complication of advanced liver cirrhosis), and Long COVID. The company also conducts research into epigenetic mechanisms, such as DNA methylation, to understand gene expression regulation.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Securities and Exchange Commission (SEC) regarding an Amendment No. 1 to a Registration Statement on Form S-1 filed by BioVie Inc. The content discusses responses to SEC comments about the registration statement, including details about a reverse stock split and disclosure requirements. Form S-1 is a registration statement used for securities offerings, which falls under capital raising activities. The document is a correspondence letter responding to regulatory comments rather than the registration statement itself or a financial report. The document length is short (3246 characters), and it is clearly a regulatory correspondence related to a capital raising filing. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory correspondence and does not contain financial statements or detailed financial data itself.
2019-07-09 English
FORM S-1 AMENDMENT NO. 2
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A (Amendment No. 2) registration statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for a public offering of shares by BioVie Inc. The document includes a preliminary prospectus with detailed information about the company, the offering, risk factors, management discussion, and financial statements. Form S-1 is used for initial public offerings or other securities registrations and is not an annual report, earnings release, or other financial report. It is a capital markets filing related to fundraising and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual filing, not just an announcement or certification.
2019-07-09 English
AW
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting withdrawal of a registration statement amendment related to a Form S-1 filing. It references regulatory rules (Rule 477 of Regulation C) and confirms no securities were sold. The content is a formal regulatory communication about a filing withdrawal, not a financial report, presentation, or announcement of voting results. The document length is short (1248 characters), and it is clearly a regulatory filing related to compliance and procedural matters rather than a report or announcement. Therefore, it fits best under Regulatory Filings (RNS).
2019-07-09 English
RW WD
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC regarding a Registration Withdrawal Request for a Registration Statement. It references Rule 477 of Regulation C and mentions the correct form type (Form AW) for the withdrawal. The content is procedural and relates to regulatory compliance about a registration withdrawal, with no financial data, report, or presentation included. The document length is short (1210 characters), and it is clearly a regulatory communication rather than a financial report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2019-07-09 English
Regulatory Filings 2019
Regulatory Filings
2019-07-08 English
FORM S-1 AMENDMENT NO. 1
Regulatory Filings Classification · 100% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is used by companies planning an initial public offering (IPO) or other securities offering to register their securities. The text includes details about the offering, company background, risk factors, use of proceeds, capitalization, management discussion and analysis, and other information typical of a prospectus. This is not an annual report, earnings release, or any other financial report type. Instead, it is a regulatory filing related to capital raising and securities registration. According to the classification definitions, this type of document fits best under Regulatory Filings (RNS), as it is a general regulatory announcement and does not fit into other specific categories like Capital/Financing Update (CAP) which is more about updates post-financing, or Share Issue/Capital Change (SHA) which is more about announcements of share issuance rather than the registration statement itself. Therefore, the correct classification is Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is a full filing, not a brief announcement or certification.
2019-07-01 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.